What We Do
Discover
new approaches to developing vaccines and other means of preventing HIV.
Accelerate
translational and clinical research through our laboratories in the U.S., India, and the U.K.
Build Capacity
in-country for researching vaccine candidates while strengthening local public health and scientific expertise.
Partner
with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.
Share
IAVI’s resources with other innovators to help the HIV community as a whole succeed.
Extend
IAVI’s core capabilities to solving disease prevention and treatment challenges.
Latest News from IAVI
IAVI Partners in Snakebite Treatment Consortium
Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.
IAVI Report: Special issue on HIV vaccine science in Africa, for Africa
The issue was inspired by the elegant science being produced by scientists in Africa and the scientific capacity being built via IAVI’s ADVANCE program.
Donor Spotlight: U.S. Agency for International Development
IAVI recognizes USAID and the American people for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.
Phase I Trial of Native-like HIV Env Trimer
Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein
Need for TB Vaccine Research Support
World TB Day falls on March 24 each year. It marks the day in 1882 when Robert Koch announced that he had identified the cause of TB.
The Need for Long-Acting HIV Prevention
Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.
Publications
